Navigation Links
Lilly Caps Successful Year with Strong Fourth-Quarter Results
Date:1/29/2008

eduction, Humalog and Byetta, offset by decreases in other areas. Research and development expenses are expected to grow in the high- single to low-double digits. Other income is expected to contribute less than $100 million. The effective tax rate is expected to be approximately 23 percent. Capital expenditures are projected to be approximately $1.1 billion.

The company expects 2008 pro forma adjusted earnings per share to be within the range of $3.85 to $4.00. The pro forma adjusted earnings per share guidance excludes an estimated $.05 charge noted in the table below related to the in-licensing transaction with BioMS. Including this $.05 charge, the company expects reported earnings per share to be in the range of $3.80 to $3.95. See the reconciliation table below for further detail.

Reconciliation of 2008 Earnings Per Share Expectations:

------------------------------------------------------

2008 2007

Expectations Results % Growth

-------------- -------------- -----------

E.P.S. (reported) $3.80 to $3.95 $2.71

Eliminate estimated in-process

research and development

charge associated with BioMS

Medical in-licensing .05

Eliminate asset impairments,

restructuring and other special

charges - .15

Eliminate charge for a reduction

in expected insurance recoveries - .06

Eliminate in-process research &

development charges associated

with ICOS, Hypnion, and Ivy

acquisitions and OSI,

MacroGenics and Glenmark

in-licensing transactions - .63

Include pro forma as if the ICOS

acquisition was completed on

January 1, 2006
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement
2. Lilly Announces Dividend Increase
3. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
4. International Federation-Lilly Agreement Will Allow Significant Increase in MDR-TB Programmes
5. JDRF and Lilly partner to fund research to identify beta cell biomarkers
6. The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa
7. Lilly Contributes $10.8 Million to United Way Annual Campaign
8. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
9. Lilly Sets Date and Time for American Heart Association Conference Call
10. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
11. Eli Lilly and Company Aids California Recovery Effort
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 ... antidepressant can quickly alter the way brain cells communicate with ... Sept. 18 in Current Biology , are a ... antidepressants. Experts said the hope is to eventually be able ... from a drug -- and which people would fare better ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
(Date:9/18/2014)... convene a one-day conference at the Milken Institute School ... September 25, 2014 to discuss the Global Health Security ... purpose of this event is to invite discussion of ... years, including action plans to curtail the current deadly ... GHSA, international organizations and more than 50 countries have ...
(Date:9/18/2014)... N.C. Dangerous new pathogens such as the Ebola ... ancient scourges such as the bubonic plague are still ... responds to infections. , In a study published online ... researchers at Duke Medicine and Duke-NUS Graduate Medical School ... bubonic plague hitchhike on immune cells in the lymph ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:New insights on an ancient plague could improve treatments for infections 2
... Orissa government has ordered administrations of all 30 districts to ... three days.// ,The officials were Thursday asked to ... senior health department official. ,These would then be ... government does not have testing facilities to confirm the presence ...
... safety lawyer, writes about why it is essential for us ... that there is a major defect in the food safety ... people affected or even killed by contaminated food products from ... it prevents our society from knowing the source of our ...
... of NSAID by women in their first trimester could ... ,Non-steroidal anti-inflammatory drugs, NSAIDs, Cardiac septal defects, Journal ... Congenital abnormality, Diabetes ,Women who take non-steroidal ... more likely to give birth to babies with congenital ...
... say that a commonly used HIV drug may be useful ... be used in prevention of the cancer and could be ... and his colleagues said that such a cream could prove ... lesions. However no clinical trials have begun as yet. ...
... hundreds of resident doctors in Delhi who had gone on ... agitation //for the next three months with the reservation bill ... the parliament has referred the reservation bill to the standing ... being. The bill will be placed in the floor of ...
... the University of Pennsylvania have disclosed that a specific ... of changing into bone, muscle, neurons or other// types ... environment. , ,The researchers found that ... bone marrow, are soliciting tangible clues from their local ...
Cached Medicine News:Health News:Importance of knowing the source of our food 2Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Medicos Suspends Anti-quota Stir 2Health News:Adult stem cells are sensitive to responses from the environment 2
(Date:9/18/2014)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... Drug Administration (FDA) has removed the clinical hold ... SWOG,s ongoing Phase 1b/2 clinical trial (S1313). The ... PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with ... pancreatic adenocarcinoma.  The study will resume under a ...
(Date:9/18/2014)... , September 18, 2014 After 6 ... community, we,re finally here - the new programme for the ... 2015, part of our global Cool Chain series, has just ... here ! As the lines between supply chain, ... together a programme that is broad and yet specific, focused ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... Becomes Squarer, Makes You Look Older, ASPS,Study Reveals, ... giving away your age, and it has nothing to ... in January,s Plastic and,Reconstructive Surgery(R) (PRS), the official medical ... that as we age, the,lower jaw continues to grow, ...
... Inc.,today announced that a paper published in ... reports that SF1126, the company,s lead product,candidate, ... paper, entitled "A Vascular Targeted Pan Phosphoinositide ... Activity," is,based on preclinical studies conducted by ...
Cached Medicine Technology:Looking Older? How Square is Your Jaw Line? 2Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity 2
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Medicine Products: